DrugInformer Search


Ingredients: Fentanyl
Average User Review Score
* Based on 2 reviews from across the web.

Duragesic and Durogesic /ˌdɜːrəˈdʒiːzɪk/ are trade names of fentanyl transdermal patches, used for relief of moderate to severe pain. The patches release fentanyl, a potent opioid, slowly through the skin. One patch may provide 72 hours of pain relief. Initial onset of effectiveness after a patch has been applied is typically 8–12 hours under normal conditions; thus, Duragesic patches are often prescribed with another opioid (such as morphine sulfate) to handle breakthrough pain.

Read more on Wikipedia

  Please use Workbench for in-depth research on Duragesic-100.

Tell us about your Experience with Duragesic-100

Thank you for sharing your experience with us!

Share Your Experience

Druginformer Identified Side Effects: None

Posted By Anonymous in everydayhealth.com on April 26, 2012 @ 12:00 am

I have had this RX prescribed for 10+ years. I have severe Fibromyalagia, Degeneratve Disc Disease, as well as a Ruptured Disc. I began taking this drug just prior to being diagnosed with Breast Cance...

Druginformer Identified Side Effects: None

Posted By Anonymous in everydayhealth.com on November 12, 2007 @ 12:00 am

I have fibromyalgia and have been on the "patch" for 2 years now. I use one patch every 48 hours instead of 72. Since I have been using them as an 48 hour basis I have had a dramatic drop in the pai...

* Warning: The facts and figures contained in these reports are accurate to the best of our capability; however, our metrics are only meant to augment your medical knowledge, and should never be used as the sole basis for selecting a new medication. As with any medical decision, be sure to work with your doctor to ensure the best choices are made for your condition.

* About FAERS: The FDA Adverse Event Reporting System (FAERS) is used by FDA for activities such as looking for new safety concerns that might be related to a marketed product, evaluating a manufacturer's compliance to reporting regulations and responding to outside requests for information. Reporting of adverse events is a voluntary process, and not every report is sent to FDA and entered into FAERS. The FAERS database may contain duplicate reports, the report quality is variable, and many factors may influence reporting (e.g., media attention, length of time a drug is marketed, market share). For these reasons, FAERS case reports cannot be used to calculate incidence or estimates of risk for a particular product or compare risks between products.